Literature DB >> 20154257

Impact of anti-apoptotic and anti-oxidative effects of bone marrow mesenchymal stem cells with transient overexpression of heme oxygenase-1 on myocardial ischemia.

Toshinari Tsubokawa1, Kunimasa Yagi, Chiaki Nakanishi, Masahiko Zuka, Atsushi Nohara, Hidekazu Ino, Noboru Fujino, Tetsuo Konno, Masa-aki Kawashiri, Hatsue Ishibashi-Ueda, Noritoshi Nagaya, Masakazu Yamagishi.   

Abstract

Although mesenchymal stem cells (MSCs) have therapeutic potential for tissue injury, intolerance and poor cell viability limit their reparative capability. Therefore, we examined the impact of bone marrow-derived MSCs, in which heme oxygenase-1 (HO-1) was transiently overexpressed, on the repair of an ischemic myocardial injury. When MSCs and HO-1-overexpressed MSCs (MSC(HO-1)) were exposed to serum deprivation/hypoxia or H(2)O(2)-induced oxidative stress, MSC(HO-1) exhibited increased resistance to cell apoptosis compared with MSCs (17 +/- 1 vs. 30 +/- 2%, P < 0.05) and were markedly resistant to cell death (2 +/- 1 vs. 32 +/- 2%, P < 0.05). Under these conditions, vascular endothelial growth factor (VEGF) production was 2.1-fold greater in MSC(HO-1) than in MSCs. Pretreatment of MSCs and MSC(HO-1) with phosphatidylinositol 3-kinase (PI 3-kinase)/protein kinase B (Akt) pathway inhibitors such as LY-294002 (50 muM) or wortmannin (100 nM) significantly decreased VEGF production. In a rat infarction model with MSCs or MSC(HO-1) (5 x 10(6) +/- 0.1 x 10(6) cells/rat) transplantation, the number of TdT-mediated dUTP nick end-labeling-positive cells was significantly lower in the MSC(HO-1) group than in the MSC group (12.1 +/- 1.0 cells/field vs. 26.5 +/- 2.6, P < 0.05) on the 4th day after cell transplantation. On the 28th day, increased capillary density associated with decreased infarction size was observed in the MSC(HO-1) group (1,415 +/- 47/mm(2) with 21.6 +/- 2.3%) compared with those in the MSCs group (1,215 +/- 43/mm(2) with 28.2 +/- 2.3%, P < 0.05), although infarction size relative to area at risk was not different in each group at 24 h after transplantation. These results demonstrate that MSC(HO-1) exhibit markedly enhanced anti-apoptotic and anti-oxidative capabilities compared with MSCs, thus contributing to improved repair of ischemic myocardial injury through cell survival and VEGF production associated with the PI 3-kinase/Akt pathway.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20154257     DOI: 10.1152/ajpheart.01330.2008

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  45 in total

Review 1.  Heme oxygenase, a novel target for the treatment of hypertension and obesity?

Authors:  Peter A Hosick; David E Stec
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-11-09       Impact factor: 3.619

Review 2.  Cardiac cell therapy: boosting mesenchymal stem cells effects.

Authors:  E Samper; A Diez-Juan; J A Montero; P Sepúlveda
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

Review 3.  Genetic engineering of mesenchymal stem cells and its application in human disease therapy.

Authors:  Conrad P Hodgkinson; José A Gomez; Maria Mirotsou; Victor J Dzau
Journal:  Hum Gene Ther       Date:  2010-10-22       Impact factor: 5.695

4.  Heritability of in vitro phenotypes exhibited by murine adipose-derived stromal cells.

Authors:  Zixuan Jiang; David E Harrison; Makayla E Parsons; Susan McClatchy; Lawrence Jacobs; Robert Pazdro
Journal:  Mamm Genome       Date:  2016-07-08       Impact factor: 2.957

5.  Protective effect of apelin on cultured rat bone marrow mesenchymal stem cells against apoptosis.

Authors:  Xiangjun Zeng; Shan Ping Yu; Tammi Taylor; Molly Ogle; Ling Wei
Journal:  Stem Cell Res       Date:  2011-12-13       Impact factor: 2.020

6.  Paracrine effects of mesenchymal stem cells in cisplatin-induced renal injury require heme oxygenase-1.

Authors:  Abolfazl Zarjou; Junghyun Kim; Amie M Traylor; Paul W Sanders; József Balla; Anupam Agarwal; Lisa M Curtis
Journal:  Am J Physiol Renal Physiol       Date:  2010-11-03

7.  The caspase-8 shRNA-modified mesenchymal stem cells improve the function of infarcted heart.

Authors:  Yeyou Liang; Qiuxiong Lin; Jiening Zhu; Xiaohong Li; Yongheng Fu; Xiao Zou; Xiaoying Liu; Honghong Tan; Chunyu Deng; Xiyong Yu; Zhixin Shan; Weiwei Yuan
Journal:  Mol Cell Biochem       Date:  2014-07-25       Impact factor: 3.396

Review 8.  Can the outcomes of mesenchymal stem cell-based therapy for myocardial infarction be improved? Providing weapons and armour to cells.

Authors:  Andrey A Karpov; Daria V Udalova; Michael G Pliss; Michael M Galagudza
Journal:  Cell Prolif       Date:  2016-11-23       Impact factor: 6.831

Review 9.  Mesenchymal stem cells at the intersection of cell and gene therapy.

Authors:  Timothy J Myers; Froilan Granero-Molto; Lara Longobardi; Tieshi Li; Yun Yan; Anna Spagnoli
Journal:  Expert Opin Biol Ther       Date:  2010-12       Impact factor: 4.388

10.  Role of heme oxygenase-1 in postnatal differentiation of stem cells: a possible cross-talk with microRNAs.

Authors:  Magdalena Kozakowska; Krzysztof Szade; Jozef Dulak; Alicja Jozkowicz
Journal:  Antioxid Redox Signal       Date:  2014-01-30       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.